2269:HKG
WuXi Biologics (Cayman) Inc
HK$48.20
arrow_downward
-0.90%(-0.44) 1D
Okt 16, 4:08:14 PM GMT+8 · HKD
search
Lahat ng simbolo
| Simbolo | Presyo | Palitan | % ng Pagbabago |
|---|
insights_autoBumubuo ng mga nangungunang insight para sa 2269...
Buksan
HK$49.98
Mataas
HK$50.85
Mababa
HK$45.82
Mkt. cap
198.43B
Avg. na dami
30.42M
Dami
55.18M
P/E ratio
34.48
Mataas nang 52-wk
HK$58.00
Mababa nang 52-wk
HK$28.48
EPS
HK$1.40
Mga natitirang share
1.23B
Bilang ng mga empleyado
15K
Buksan
HK$49.98
Mataas
HK$50.85
Mababa
HK$45.82
Mkt. cap
198.43B
Avg. na dami
30.42M
Dami
55.18M
P/E ratio
34.48
Mataas nang 52-wk
HK$58.00
Mababa nang 52-wk
HK$28.48
EPS
HK$1.40
Mga natitirang share
1.23B
Bilang ng mga empleyado
15K
Mga balita at kwento
Mula sa mga source sa web at partner sa balita
MarketWatch
·
13 oras ang nakalipas
These surprising stocks could be some of the biggest drivers of S&P 500 earnings growth
Bloomberg.com
·
5 oras ang nakalipas
US Stock Futures Rise Ahead of Busy Earnings Week: Markets Wrap
24/7 Wall St.
·
5 araw ang nakalipas
These 3 International Dividend ETFs Outyield SCHD and Are Beating the S&P 500 Over the Past Year
MarketWatch
·
1 buwan ang nakalipas
Bloom Energy was just named to the S&P 500. These other stocks are joining the index as well.
Profile
WuXi Biologics is a global Contract Research Development and Manufacturing Organization that provides open-access, integrated technology platforms for biologics drug development.
WuXi Biologics' roots date back to 2010, when it was founded as a division of WuXi AppTec and began building out capabilities and facilities required for biologics discovery, development and good manufacturing practices. After being spun off from its parent, WuXi Biologics went public on the Hong Kong Stock Exchange in June 2017.
As of 2021, WuXi Biologics has 18 manufacturing sites including ten in China, three in the United States, two in Ireland, two in Germany, and one in Singapore.
In August 2020, WuXi Biologics was selected to become a component of the Hang Seng Index in Hong Kong.
In January 2024, WuXi Biologics' share price fell on news that the United States Congress had introduced legislation to block any federal government contracts with the company due to national security concerns. The concerns stem from allegations, denied by the company, that it has worked closely with the People's Liberation Army as a part of the Chinese Communist Party's military-civil fusion strategy. Wikipedia
Tungkol sa WuXi Biologics (Cayman) Inc